Cantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price Target

Cantor Fitzgerald set a $19.00 target price on Advaxis (NASDAQ:ADXS) in a research report sent to investors on Thursday morning. The firm currently has a buy rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Advaxis’ FY2018 earnings at ($2.28) EPS.

Other equities analysts have also issued reports about the stock. ValuEngine upgraded shares of Advaxis from a strong sell rating to a sell rating in a research note on Friday, September 8th. HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a buy rating in a research note on Wednesday, December 27th. Finally, BidaskClub upgraded shares of Advaxis from a hold rating to a buy rating in a research note on Saturday, September 9th.

Shares of Advaxis (ADXS) opened at $2.84 on Thursday. Advaxis has a one year low of $2.71 and a one year high of $10.06. The firm has a market cap of $117.30, a P/E ratio of -1.23 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last released its earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. analysts forecast that Advaxis will post -2.36 EPS for the current fiscal year.

In other Advaxis news, insider Robert Petit sold 12,625 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,273.75. Following the transaction, the insider now directly owns 237,265 shares in the company, valued at $756,875.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Insiders sold 632,968 shares of company stock worth $2,686,002 over the last quarter. 7.21% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its holdings in shares of Advaxis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after acquiring an additional 817 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Advaxis by 2.6% in the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 1,144 shares during the period. Rhumbline Advisers boosted its holdings in shares of Advaxis by 3.7% in the second quarter. Rhumbline Advisers now owns 42,508 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 1,530 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of Advaxis by 2.4% in the second quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock valued at $637,000 after acquiring an additional 2,329 shares during the period. Finally, Northern Capital Management LLC boosted its holdings in shares of Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 2,650 shares during the period. Institutional investors own 41.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price Target” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2018/01/01/cantor-fitzgerald-analysts-give-advaxis-adxs-a-19-00-price-target.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

What are top analysts saying about Advaxis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Advaxis and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit